Exelixis EXEL NASDAQ · Healthcare · United States
$65.83 -3.60% -$2.46
Summary
84 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 71% a year over the last 3 years.
- Out of every 100 USD of revenue, 35 USD is left as net profit.
- It earns 40 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $304.8M against $162.2M.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 18.7 USD for 1 USD of yearly profit. Over the last five years it was 25.2 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 13% a year. For the next fiscal year analysts expect revenue to grow by 13%. Earnings per share grew by 71% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 3.7 USD
- Research and development 33 USD
- Sales and administration 23 USD
- Taxes and other 4.7 USD
- Net profit 35 USD
Net profit, industry median (Biotechnology) -9.2 USD
Out of every 100 USD of revenue, 35 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 15
- Hold 18
- Sell 0
Today's price within the analysts' price targets
The average target of $53 is 19% below today's price. 45% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product, Gross 54%
- Product 38%
- License 3.9%
- Collaboration 3.6%
By region
- UNITED STATES 92%
- Europe 6.6%
- JAPAN 1.1%
Product, Gross brings in 54% of revenue.
Segments in detail